iwCAR-T Virtual Meeting

iwCAR T

VJHemOnc is the official media partner of the iwCAR-T Virtual Meeting!

This virtual workshop will cover trial updates and the latest thinking in CAR-T & cellular therapies from international leading experts in hematological oncology, featuring cutting edge presentations and live interactive panel discussions.

Register your place before the 29th of October!

https://register.gotowebinar.com/register/7327584602578872591

Program (all times in EST)


Thursday: October 29 2020

10:00 AM
Introduction & Meeting Objectives
John Gribben & David Maloney

10:05 – 11:25 AM
Session I: CAR-T in ALL
Chairs: Noelle Frey & Bijal Shah

  • Novel CAR-T approaches for ALL: Rebecca Gardner
  • CAR-T in adult ALL: Claire Roddie
  • Allogeneic CAR-T in ALL: Bijal Shah
  • Remission & Persistence: Shannon Maude

Panel discussion

11:25 – 12:45 PM
Session II: CAR-T in AML
Chairs: Saar Gill & John DiPersio

  • Overview: Saar Gill
  • CAR-T vs BiTEs for AML: John DiPersio
  • NKG2D and anti-CD33 CAR-T: David Sallman
  • CART-123 for AML: Elizabeth Budde

Panel discussion

12:45 – 14:00 PM
Session III: CAR-T in CLL
Chairs: John Gribben & David Porter

  • Update CLL CAR-T trial landscape/JCAR: Tanya Siddiqi
  • Long-term outcomes of anti-CD19 CAR-T in R/R CLL: David Porter
  • CAR-T NK treatments in CLL: Katy Rezvani
  • The role of CLL tumor cells in resistance to anti-CAR-T cell therapy: Joseph Melenhorst

Panel discussion

End of scientific session, Day 1

Friday: October 30 2020

10:00 AM
Introduction from co-chairs
John Gribben & David Maloney

10:00 – 11:15 AM
Session IV: CAR-T in Lymphoma
Chairs: Fred Locke & Caron Jacobsen

  • CD19-CAR T-cells - trial updates: Jeremy Abramson
  • CD30 update: Barbara Savoldo
  • CD5 and CD7 CAR T-cells: Max Mamonkin

Panel discussion

11:15 – 12:35 PM
Session V: CAR-T in Myeloma
Chairs: Yi Lin & Noopur Raje

  • BCMA CAR-T - ready for standard of care practice?: Nina Shah
  • CAR-T trials in China: myeloma and CAR-T landscape in China: Jianxiang Wang
  • BiTEs vs CARs: Hermann Einselle
  • Beyond BCMA, other novel CAR-T targets and combinations: Eric Smith

Panel discussion

12:35 – 13:50 PM
Session V: Evolution of cellular therapies
Chairs: David Maloney & TBC

  • Tmod CAR T-cells targeting loss of heterozygosity: William Go
  • Repeat CAR-T infusions (ALL, NHL, CLL): Jordan Gauthier
  • Informed design of engineered T-cell therapies for cancer: Stan Riddell
  • Novel CAR platforms - allogeneic CAR-T, CAR-NK: Michael Hudecek

Panel discussion

Final meeting summary & conclusions

Kontakt telefon

033 297 160

Kontakt email

info@uhit.ba